01 November 2018
Visiongain has launched a new pharma report: Global Genomics Market Report 2018-2028: Sequencing, Microarray, PCR, Nucleic Acid Extraction and Purification, Diagnostic Test, Genetic Test, Newborn Screening, Preimplantation Testing, Prenatal Testing, Carrier Testing, Molecular Test, Chromosomal Test, Biochemical Test, Diagnostic, Drug Discovery, Precision Medicine, Research Centers, Hospitals and Clinics, Pharmaceutical Companies and Others.
Genome-based research is already empowering medical researchers to develop improved diagnostics, more effective therapeutic strategies, evidence-based approaches for demonstrating clinical efficacy, and better decision-making tools for patients and providers. The genomics market has been segmented based on technology, test type, method, application, end-user, and geography.
The lead analyst of the report commented "Genomics market is quite fragmented. Companies are investing in research and development activities and the industry growth is highly positive. There is a strong and established customer base for genomics market which is continually progressing. The products are very much undifferentiated as the technological arena is limited to certain extents and, each application segment is demanding technological advancement.
With increasing demand for diagnostic and precision medicines, market players are introducing product developments to differentiate themselves with the best and cost-effective solutions to the market. There is a presence of many domestic and global level players with intense competition among each other."
Leading companies featured in the report include Agilent Technologies, Inc., Danaher Corporation, Eppendorf AG, BGI Genomics Co. Ltd., Eurofins Scientific, GE Healthcare Life Sciences, Illumina, Inc., Oxford Nanopore Technologies Ltd., Qiagen NV, Roche, Thermo Fisher Scientific, Inc.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.
05 July 2019
Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.
28 June 2019
Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.
25 June 2019
Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.